EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

β-Glucan Supplementation in Chronic Disease Management: A Systematic Review of Randomized Controlled Trials

Jing Tang, Yingjie Cai, Ziwei Guo, Lichun Qiao, Licheng Yang, Pei Li, Jing Han

Nutrients · 17.11.2026 · 18 (22) · 3813

DOI: 10.3390/nu18223813 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Nutrients, online erschienen am 17.11.2026. Verfasst von Jing Tang und 6 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dietary polysaccharides are being investigated as adjuncts to chronic disease management, but their clinical effects may vary across preparations and patient populations. This systematic review evaluated randomized controlled trials (RCTs) of oral dietary polysaccharide interventions in patients with chronic diseases or related clinical conditions.

Methods

PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials were searched from inception to September 2026. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the Cochrane RoB 2 tool. Given substantial clinical and methodological heterogeneity, findings were synthesized narratively.

Results

Twenty-five reports from 24 RCTs were included, all evaluating β-glucan interventions derived from oats, barley, or fungi. Several trials reported reductions in low-density lipoprotein cholesterol (LDL-C), particularly with oat β-glucan, although results differed across preparations and populations. Effects on glycemic control, body weight, and other anthropometric outcomes were inconsistent. Cancer trials reported changes in selected immune markers without establishing survival benefits. One trial in chronic gastritis reported reduced gastric mucosal inflammation with a high-molar-mass oat β-glucan preparation. Risk of bias was rated as “some concerns” in 22 trials and low in two.

Conclusions

Evidence most consistently supported LDL-C lowering with oat β-glucan in selected populations. Heterogeneity, short treatment durations, and risk-of-bias concerns limit broader clinical conclusions. Larger, longer RCTs using standardized preparations and clinically relevant outcomes are needed.

Zitieren

APA

Tang, J., Cai, Y., Guo, Z., Qiao, L., Yang, L., Li, P., & Han, J. (2026). β-Glucan Supplementation in Chronic Disease Management: A Systematic Review of Randomized Controlled Trials. Nutrients, 18(22), 3813. https://doi.org/10.3390/nu18223813

Vancouver

Tang J, Cai Y, Guo Z, Qiao L, Yang L, Li P, et al. β-Glucan Supplementation in Chronic Disease Management: A Systematic Review of Randomized Controlled Trials. Nutrients. 2026;18(22):3813. doi:10.3390/nu18223813

BibTeX
@article{Tang2026,
  author = {Tang, Jing and Cai, Yingjie and Guo, Ziwei and Qiao, Lichun and Yang, Licheng and Li, Pei and Han, Jing},
  title = {β-Glucan Supplementation in Chronic Disease Management: A Systematic Review of Randomized Controlled Trials},
  journal = {Nutrients},
  year = {2026},
  volume = {18},
  number = {22},
  pages = {3813},
  doi = {10.3390/nu18223813}
}
Kostenlos starten →